The disease HCHWA-D is the genetic variant of the CAA disease.
The disease CAA (Cerebral Amyloid Angiopathy) occurs in the small blood vessels of the brain. Amyloid deposits (toxic proteins) attach themselves to the wall of the blood vessels. This causes recurring brain haemorrhages and infarcts, which can lead to i.e. paralysis, vascular dementia and ultimately death. 1 in 4 people over the age of 60 develops CAA. This number continues to increase according to the Dutch CAA foundation.
The characteristics and development of CAA is similar to that of HCHWA-D. Difference: the number of CAA cases is much higher than that of HCHWA-D. Another important distinction: CAA is undetectable whereas HCHWA-D can be detected through genetic testing.
HCHWA-D (in comparison with CAA) in brief:
There are many similarities between the diseases CAA and HCHWA-D. More knowledge of HCHWA-D, as the genetic variant, will aid the fight against CAA, which is a far more frequently occurring (and therefore more deadly) disease. Research on genetic carriers of the HCHWA-D genome could possibly lead to the discovery of a treatment and perhaps even to a cure of the disease.
But ongoing research requires funding is required something which both CAA and HCHWA-D carriers and their relatives can ben It is therefore Thus, funding for research would be beneficial to both carriers and stakeholders of the two groups as, the key to therapy for CAA/HCHWA-, has not yet been found. Companies and individuals can support the HCHWA-D association as a sponsor.